These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 24093956

  • 21. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
    Ma Y, Liu W, Zhang L, Jia G.
    Med Sci Monit; 2017 Oct 29; 23():5150-5157. PubMed ID: 29080899
    [Abstract] [Full Text] [Related]

  • 22. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
    Cheng YW, Liao LD, Yang Q, Chen Y, Nie PJ, Zhang XJ, Xie JJ, Shan BE, Zhao LM, Xu LY, Li EM.
    Cell Biochem Funct; 2018 Dec 29; 36(8):398-407. PubMed ID: 30484863
    [Abstract] [Full Text] [Related]

  • 23. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
    Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, Pan JF, Fan J, Zhou J.
    World J Gastroenterol; 2011 Sep 14; 17(34):3922-32. PubMed ID: 22025881
    [Abstract] [Full Text] [Related]

  • 24. Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
    Yan-Fang T, Zhi-Heng L, Li-Xiao X, Fang F, Jun L, Gang L, Lan C, Na-Na W, Xiao-Juan D, Li-Chao S, Wen-Li Z, Pei-Fang X, He Z, Guang-Hao S, Yan-Hong L, Yi-Ping L, Yun-Yun X, Hui-Ting Z, Yi W, Mei-Fang J, Lin L, Jian N, Shao-Yan H, Xue-Ming Z, Xing F, Jian W, Jian P.
    PLoS One; 2015 Sep 14; 10(7):e0126566. PubMed ID: 26176219
    [Abstract] [Full Text] [Related]

  • 25. Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1.
    Zhang H, Tan YP, Zhao L, Wang L, Fu NJ, Zheng SP, Shen XF.
    Cell Death Dis; 2020 Jan 24; 11(1):63. PubMed ID: 31980595
    [Abstract] [Full Text] [Related]

  • 26. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
    Catalano MG, Pugliese M, Gargantini E, Grange C, Bussolati B, Asioli S, Bosco O, Poli R, Compagnone A, Bandino A, Mainini F, Fortunati N, Boccuzzi G.
    Int J Cancer; 2012 Feb 01; 130(3):694-704. PubMed ID: 21400508
    [Abstract] [Full Text] [Related]

  • 27. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA, Growdon WB, Rueda BR, Foster R.
    J Ovarian Res; 2016 Sep 15; 9(1):58. PubMed ID: 27633667
    [Abstract] [Full Text] [Related]

  • 28. Euphorbia factor L2 inhibits TGF-β-induced cell growth and migration of hepatocellular carcinoma through AKT/STAT3.
    Fan L, Zhu H, Tao W, Liu L, Shan X, Zhao M, Sun D.
    Phytomedicine; 2019 Sep 15; 62():152931. PubMed ID: 31085375
    [Abstract] [Full Text] [Related]

  • 29. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines.
    Henrici A, Montalbano R, Neureiter D, Krause M, Stiewe T, Slater EP, Quint K, Ocker M, Di Fazio P.
    Mol Carcinog; 2015 Aug 15; 54(8):585-97. PubMed ID: 24375802
    [Abstract] [Full Text] [Related]

  • 30. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
    Vallo S, Mani J, Stastny M, Makarević J, Juengel E, Tsaur I, Bartsch G, Haferkamp A, Blaheta RA.
    Invest New Drugs; 2013 Apr 15; 31(2):265-72. PubMed ID: 22801803
    [Abstract] [Full Text] [Related]

  • 31. ZnAs@SiO2 nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1/JAK2/STAT3 signaling.
    Huang Y, Zhou B, Luo H, Mao J, Huang Y, Zhang K, Mei C, Yan Y, Jin H, Gao J, Su Z, Pang P, Li D, Shan H.
    Theranostics; 2019 Apr 15; 9(15):4391-4408. PubMed ID: 31285768
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC, Huang HH, Lai CY, Lin YJ, Liou JP, Lai MJ, Li YH, Teng CM, Yang CR.
    Oncotarget; 2016 Jan 05; 7(1):402-17. PubMed ID: 26587975
    [Abstract] [Full Text] [Related]

  • 34. Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines.
    Di Fazio P, Montalbano R, Neureiter D, Alinger B, Schmidt A, Merkel AL, Quint K, Ocker M.
    Exp Cell Res; 2012 Sep 10; 318(15):1832-43. PubMed ID: 22683924
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Total alkaloids of Rubus aleaefolius Poir. inhibit the STAT3 signaling pathway leading to suppression of proliferation and cell cycle arrest in a mouse model of hepatocellular carcinoma.
    Zhao J, Lin W, Cao Z, Liu L, Zhuang Q, Zhong X, Hong Z, Peng J.
    Oncol Rep; 2013 Sep 10; 30(3):1309-14. PubMed ID: 23828071
    [Abstract] [Full Text] [Related]

  • 38. Histone deacetylase inhibitor quisinostat activates caspase signaling and upregulates p53 acetylation to inhibit the proliferation of HepG2 cells.
    Li F, Wang T, Wang Z, Chen X, Liu R.
    Mol Med Rep; 2017 Nov 10; 16(5):6094-6101. PubMed ID: 28849080
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.